These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32157523)

  • 1. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds.
    Meneses D; Olveira A; Corripio R; Del Carmen Méndez M; Romero M; Calvo-Viñuelas I; Herranz L; Vicent D; de-Cos-Blanco AI
    Obes Surg; 2020 Jul; 30(7):2538-2546. PubMed ID: 32157523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
    Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
    Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease.
    de Carli MA; de Carli LA; Correa MB; Junqueira G; Tovo CV; Coral GP
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):420-425. PubMed ID: 31464779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acoustic radiation force impulse elastography and liver fibrosis risk scores in severe obesity.
    da Silva RG; de Miranda MLQ; de Araújo Caldeira Brant PE; Schulz PO; de Fátima Araujo Nascimento M; Schmillevitch J; Vieira A; de Freitas WR; Szutan LA
    Arch Endocrinol Metab; 2021 Nov; 65(6):730-738. PubMed ID: 34762779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.
    Alqahtani SA; Golabi P; Paik JM; Lam B; Moazez AH; Elariny HA; Goodman Z; Younossi ZM
    Obes Surg; 2021 May; 31(5):2002-2010. PubMed ID: 33616848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
    Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.